Posted by Michael Wonder on 26 Nov 2015
Praxbind (idarucizumab) approved in European Union for the specific reversal of Pradaxa (dabigatran etexilate mesylate)
26 November 2015 - Idarucizumab is the first specific reversal agent for a non-vitamin K antagonist oral anticoagulant to be approved in the European union.
For more details, go to: http://www.boehringer-ingelheim.com/news/news_releases/press_releases/2015/26_november_2015_pradaxa.html
